Novast Laboratories prices IPO to raise ~$140M
What's the deal? Nantong Novast Laboratories has priced its initial public offering to raise US$128.7M, or roughly $140 million. The pharmaceutical company set the terms in September 2026.
Why now? The IPO gives Novast access to public capital markets after building out its drug development operations.
The signal: The listing adds to a run of pharmaceutical companies tapping Chinese public markets for growth funding.
Read more: in.marketscreener.com
Image credit: Generated with Gemini
